Energy restriction as an antitumor target

Future Oncology

Volumn 6, Issue 11, 2010, Pages 1675-1679

  Omar, Hany A ^a   Berman Booty, Lisa ^a   Kulp, Samuel K ^a   Chen, Ching Shih ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

cancer therapeutic agent; energy restriction; glycolysis; tumor metabolism; Warburg effect

Indexed keywords

ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE CITRATE LYASE; BIGUANIDE; BROMOPYRUVIC ACID; DEOXYGLUCOSE; DICHLOROACETIC ACID; ENZYME INHIBITOR; FX 11; GEMCITABINE; GLUCOSE DERIVATIVE; GLUFOSFAMIDE; HEPTAPEPTIDE; LONIDAMINE; METFORMIN; OSU CG12; OXIDOREDUCTASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; PHENFORMIN; RESVERATROL; TLN 232; UNCLASSIFIED DRUG;

AMPLICON; B CELL LYMPHOMA; BREAST TUMOR; ENERGY; GLIOBLASTOMA; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; ENERGY INTAKE; GLYCOLYSIS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 78650217743     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.130     Document Type: Review

References (71)

1. Hsu PP, Sabatini DM: Cancer cell metabolism: Warburg and beyond. Cell 134(5), 703-707 (2008).
2. Kaelin WG Jr, Thompson CB: Q&A: cancer: clues from cell metabolism. Nature 465(7298), 562-564 (2010).
3. Kim JW, Dang CV: Cancer's molecular sweet tooth and the Warburg effect. Cancer Res. 66(18), 8927-8930 (2006).
4. Kroemer G, Pouyssegur J: Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13(6), 472-482 (2008).
5. Seyfried TN, Shelton LM: Cancer as a metabolic disease. Nutr. Metab. (Lond.) 7, 7 (2010).
6. Zhivotovsky B, Orrenius S: The Warburg effect returns to the cancer stage. Semin. Cancer Biol. 19(1), 1-3 (2009).
7. Dang CV: c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 19(1), 1-11 (1999).
8. Elstrom RL, Bauer DE, Buzzai M et al.: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64(11), 3892-3899 (2004).
9. Garber K: Energy boost: the Warburg effect returns in a new theory of cancer. J. Natl Cancer Inst. 96(24), 1805-1806 (2004).
10. Soucek T, Cumming R, Dargusch R, Maher P, Schubert D: The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid-b peptide. Neuron 39(1), 43-56 (2003).
11. Guo S, Bragina O, Xu Y et al.: Glucose up-regulates HIF-1a expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status. J. Neurochem. 105(5), 1849-1860 (2008).
12. Pani G, Colavitti R, Bedogni B et al.: Mitochondrial superoxide dismutase: a promising target for new anticancer therapies. Curr. Med. Chem. 11(10), 1299-1308 (2004).
13. Hempel N, Ye H, Abessi B, Mian B, Melendez JA: Altered redox status accompanies progression to metastatic human bladder cancer. Free Radic. Biol. Med. 46(1), 42-50 (2009).
14. Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033 (2009).
15. Bui T, Thompson CB: Cancer's sweet tooth. Cancer Cell 9(6), 419-420 (2006).
16. Fantin VR, St-Pierre J, Leder P: Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9(6), 425-434 (2006).
17. Jiang W, Zhu Z, Thompson HJ: Dietary energy restriction modulates the activity of AMP-activated protein kinase, Akt, and mammalian target of rapamycin in mammary carcinomas, mammary gland, and liver. Cancer Res. 68(13), 5492-5499 (2008).
18. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC: Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. Annu. Rev. Med. 54, 131-152 (2003).
19. Berrigan D, Perkins SN, Haines DC, Hursting SD: Adult-onset calorie restriction and fasting delay spontaneous tumorigenesis in p53-defcient mice. Carcinogenesis 23(5), 817-822 (2002).
20. Mukherjee P, Sotnikov AV, Mangian HJ et al.: Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J. Natl Cancer Inst. 91(6), 512-523 (1999).
21. Kritchevsky D: Caloric restriction and experimental carcinogenesis. Toxicol. Sci. 52(Suppl. 2), 13-16 (1999).
22. Hartman AL, Vining EP: Clinical aspects of the ketogenic diet. Epilepsia 48(1), 31-42 (2007).
23. Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J. Am. Coll. Nutr. 14(2), 202-208 (1995).
24. Chiorean EG, Dragovich T, Hamm J et al.: A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemother. Pharmacol. 61(6), 1019-1026 (2008).
25. Ciuleanu TE, Pavlovsky AV, Bodoky G et al.: A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur. J. Cancer 45(9), 1589-1596 (2009).
26. Swinnen JV, Beckers A, Brusselmans K et al.: Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype. Cancer Res. 65(6), 2441-2448 (2005).
27. Rattan R, Giri S, Singh AK, Singh I: 5-aminoimidazole-4-carboxamide-1-b- D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280(47), 39582-39593 (2005).
28. Xiang X, Saha AK, Wen R, Ruderman NB, Luo Z: AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321(1), 161-167 (2004). (Pubitemid 39055618)
29. Buzzai M, Jones RG, Amaravadi RK et al.: Systemic treatment with the antidiabetic drug metformin selectively impairs p53-defcient tumor cell growth. Cancer Res. 67(14), 6745-6752 (2007).
30. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD: Metformin and reduced risk of cancer in diabetic patients. BMJ 330(7503), 1304-1305 (2005).
31. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR: Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33(6), 1304-1308 (2010).
32. Liu B, Fan Z, Edgerton SM et al.: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8(13), 2031-2040 (2009).
33. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 67(22), 10804-10812 (2007).
34. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M: Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 66(21), 10269-10273 (2006).
35. Guo D, Hildebrandt IJ, Prins RM et al.: The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc. Natl Acad. Sci. USA 106(31), 12932-12937 (2009).
36. Baur JA, Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 5(6), 493-506 (2006).
37. Cucciolla V, Borriello A, Oliva A et al.: Resveratrol: from basic science to the clinic. Cell Cycle 6(20), 2495-2510 (2007).
38. Bishayee A: Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev. Res. (Phila.) 2(5), 409-418 (2009).
39. Wei S, Kulp SK, Chen CS: Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem. 285(13), 9780-9791 (2010).
40. Lin JN, Lin VC, Rau KM et al.: Resveratrol modulates tumor cell proliferation and protein translation via SIRT1-dependent AMPK activation. J. Agric. Food Chem. 58(3), 1584-1592 (2010).
41. Athar M BJ, Kopelovich L, Bickers DR, Kim AL: Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms. Arch. Biochem. Biophys. 486, 95-102 (2009).
42. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ: Resveratrol induces apoptosis in chemoresistant cancer cells via modulation of AMPK signaling pathway. Ann. NY Acad. Sci.1095, 441-448 (2007).
43. Jang M, Cai L, Udeani GO et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275(5297), 218-220 (1997).
44. Athar M, Back JH, Tang X et al.: Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 224(3), 274-283 (2007).
45. Boocock DJ, Faust GE, Patel KR et al.: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev. 16(6), 1246-1252 (2007).
46. Wenzel E, Soldo T, Erbersdobler H, Somoza V: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 49(5), 482-494 (2005).
47. Niles RM, Cook CP, Meadows GG et al.: Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J. Nutr. 136(10), 2542-2546 (2006).
48. Mathupala SP, Ko YH, Pedersen PL: Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25(34), 4777-4786 (2006).
49. De Lena M, Lorusso V, Latorre A et al.: Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A Phase II study. Eur. J. Cancer 37(3), 364-368 (2001).
50. Portalone L, Lombardi A, Antilli A et al.: Treatment of inoperable non-small cell lung carcinoma stage IIIb and IV with cisplatin, epidoxorubicin, vindesine and lonidamine: a Phase II study. Tumori 85(4), 239-242 (1999).
51. De Marinis F, Rinaldi M, Ardizzoni A et al.: The role of vindesine and lonidamine in the treatment of elderly patients with advanced non-small cell lung cancer: a Phase III randomized FONICAP trial. Italian Lung Cancer Task Force. Tumori 85(3), 177-182 (1999).
52. Oudard S, Carpentier A, Banu E et al.: Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme. J. Neurooncol. 63(1), 81-86 (2003).
53. Ko YH, Smith BL, Wang Y et al.: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun. 324(1), 269-275 (2004).
54. Kim W, Yoon JH, Jeong JM et al.: Apoptosis-inducing antitumor effcacy of hexokinase II inhibitor in hepatocellular carcinoma. Mol. Cancer Ther. 6(9), 2554-2562 (2007).
55. Buijs M, Vossen JA, Geschwind JF et al.: Specifcity of the anti-glycolytic activity of 3-bromopyruvate confrmed by FDG uptake in a rat model of breast cancer. Invest. New Drugs 27(2), 120-123 (2009).
56. Chen Z, Lu W, Garcia-Prieto C, Huang P: The Warburg effect and its cancer therapeutic implications. J. Bioenerg. Biomembr. 39, 267-274 (2007).
57. Sols A, Crane RK: Substrate specifcity of brain hexokinase. J. Biol. Chem. 210(2), 581-595 (1954).
58. Tower DB: The effects of 2-deoxy-D-glucose on metabolism of slices of cerebral cortex incubated in vitro. J. Neurochem. 3(2), 185-205 (1958).
59. Hightower LE: Stress proteins in biology and medicine. In: Cold Spring Harbor Monograph Series 19. Morimoto RI, Tissieres A, Georgopoulos C (Eds). Cold Spring Harbor Laboratory, NY, USA, 572-573 (1990).
60. Little E, Ramakrishnan M, Roy B, Gazit G, Lee AS: The glucose-regulated proteins (GRP78 and GRP94): functions, gene regulation, and applications. Crit. Rev. Eukaryot. Gene Expr. 4(1), 1-18 (1994).
61. Kern KA, Norton JA: Inhibition of established rat fbrosarcoma growth by the glucose antagonist 2-deoxy-D-glucose. Surgery 102(2), 380-385 (1987).
62. Cay O, Radnell M, Jeppsson B, Ahren B, Bengmark S: Inhibitory effect of 2-deoxy-D-glucose on liver tumor growth in rats. Cancer Res. 52(20), 5794-5796 (1992).
63. Geschwind JF, Georgiades CS, Ko YH, Pedersen PL: Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev. Anticancer. Ther. 4(3), 449-457 (2004).
64. Maher JC, Krishan A, Lampidis TJ: Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother. Pharmacol. 53(2), 116-122 (2004).
65. Maschek G, Savaraj N, Priebe W et al.: 2-deoxy-D-glucose increases the effcacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64(1), 31-34 (2004).
66. Christofk HR, Vander Heiden MG, Harris MH et al.: The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 452(7184), 230-233 (2008).
67. Hersey P, Watts RN, Zhang XD, Hackett J: Metabolic approaches to treatment of melanoma. Clin. Cancer Res. 15(21), 6490-6494 (2009).
68. Le A, Cooper CR, Gouw AM et al.: Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc. Natl Acad. Sci. USA 107(5), 2037-2042 (2010).
69. Michelakis ED, Webster L, Mackey JR: Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br. J. Cancer 99(7), 989-994 (2008).
70. Sonveaux P, Vegran F, Schroeder T et al.: Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118(12), 3930-3942 (2008).
71. Hatzivassiliou G, Zhao F, Bauer DE et al.: ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 8(4), 311-321 (2005).